Summary The 'deleted in colon carcinoma' (DCC) gene has been considered a candidate tumour-suppressor gene that encodes for a transmembrane protein with strong structural similarity to members of the superfamily of neural cell adhesion molecules. It has been mapped to the chromosomal region 18q21 .1 and it is implicated in cellular differentiation and developmental processes. In human osteosarcoma allelic loss frequently occurs on the long arm of chromosome 18, suggesting a possible involvement of the DCC gene in the pathogenesis of this tumour entity. In the present study the mRNA and protein expression and rearrangements at the DNA level of the DCC gene were addressed in 25 osteosarcomas and several tumour cell lines, including osteosarcoma-and colon carcinoma-derived cell lines. Using an reverse transcriphase polymerase chain reach in (RT-PCR)-based approach DCC expression was found to be lost or substantially reduced in 14 of 19 high-grade osteosarcomas, in three of six lower grade osteosarcomas and most of the tumour cell lines, in contrast to normally differentiated osteoblasts. Immunohistochemical studies on DCC protein expression of 14 selected tumours correlated well with the RT-PCR-based results. In view of the putative tumour-suppressor characteristics of the DCC gene its loss or reduction of expression could be a specific event in the development or progression of many high-grade osteosarcomas.
Consistent chromosomal losses in human malignancies often imply that the affected region may contain a tumour-suppressor gene. In osteosarcomas frequent allelic deletions have been detected at chromosome arms 3q, 13q, 17p and 18q, the latter of which has been found to be affected in 7 of 11 investigated tumours (Yamaguchi et al, 1992) . In 1990, a putative tumoursuppressor gene was identified and has been mapped to the chromosomal region 18q2 1.1. Based on studies on allelic delections in colorectal cancer it has been termed 'deleted in colon carcinoma (DCC) gene' (Fearon et al, 1990) .
Its open reading frame comprises 29 exons that encode for a transmembrane neural cell adhesion molecule consisting of four immunoglobulin-like and six fibronectin type III-like extracellular domains and a still poorly characterized intracytoplasmic domain . In colorectal cancer a homozygous deletion, point mutations and DNA insertions have been observed within the DCC gene. Moreover, loss of heterozygosity (LOH) and reduction or loss of expression of the DCC transcript are common in prostate, breast, oesophageal, endometrial, glial and germ-cell cancer, as well as some haematological malignancies (Cropp et al, 1990; Hohne et al, 1992 ; Uchino et al, 1992 ; Gao et al, 1993; Miyake et al, 1993; Porfiri et al, 1993; Scheckr Coons, 1993; Thompson et al, 1993) .
Results of functional in vitro studies such as cytomegalovirus expression vector-mediated DCC cDNA transfection experiments or antisense RNA strategies to DCC endorse its role as a tumoursuppressor gene (Narayanan et al, 1992; Klingelhutz et al, 1995) . The DCC gene has been implicated in terminal cellular differentiation and developmental processes, perhaps through control of cell-cell or cell-extracellular matrix interactions. Like other cell adhesion molecules DCC is expressed at the cell surface but at relatively low levels, thus suggesting that its role may rather be that of a signal-transducing receptor than an anchorage protein mechanically preserving cellular texture . Its loss may confer a growth advantage on evolving cells. In human osteosarcoma the frequently observed loss of heterozygosity at chromosome arms 13q and 17p may involve the retinoblastoma and p53 tumour-suppressor genes (Friend et al, 1986; Toguchida et al, 1989; Miller et al, 1990; Mulligan et al, 1990) whereas the candidate genes within the LOH loci at chromosome arms 3q and 18q are still undefined. The localization of the DCC gene at the chromosomal region 1 8q21.1 may suggest its involvement in the pathogenesis of this tumour entity. To prove this hypothesis we assessed 25 specimens of human osteosarcoma from 22 patients and various osteosarcoma-and other childhood sarcoma-derived cell lines with regard to mRNA and protein expression and DNA rearrangement of the DCC gene. Various normally differentiated mesenchymal tissues, including osseous specimens and several colon carcinoma cell lines with known expression pattems of the DCC gene (Fearon et al, 1990) were included in the study.
MATERIALS AND METHODS
Tissue specimens Twenty-five human osteosarcomas were obtained from 22 patients who underwent surgery at the University Clinic HamburgEppendorf or associated treatment centres of the Cooperative Osteosarcoma Study Group (Winkler et al, 1988) . The selection of Presented in part at the AACR meeting 'Cancer-the interface between basic and applied research', Baltimore, 5-8 November 1995. Total RNA isolation and DNA extraction
Osteosarcoma tissue was submerged in liquid nitrogen and subsequently ground to powder by a microdismembrator (Braun Biotech Int.). Normal cortical bone specimens were smashed to small fragments and subsequently washed twice in Hanks' solution for 30 s to remove adherent non-osseous cells. Cells were lysed in guanidine-thiocyanate buffer. DNA and total RNA were isolated after ultracentrifugation on a caesium chloride cushion (Chirgwin et al, 1979) . In cases of insufficient yield of total RNA we used a monophasic solution of phenol and guanidine-thiocyanate (Chomczynski and Sacchi, 1987) .
DNA blot analysis
An aliquot of 10 Htg of EcoRI-digested genomic DNA was electrophoresed on a 0.8% agarose gel and transferred to a Gene Screen Plus nylon membrane (DuPont). Nylon filters were hybridized with a [32P]-CTP-labelled DCC 1.65kb cDNA probe comprising nucleotides 591-2250 (exons 3-15) of the DCC cDNA sequence for 18 h at 65°C. Washes and autoradiography were performed as described previously (Maniatis et al, 1989) .
Reverse transcriptase-polymerase chain reaction (RT-PCR)
An aliquot of 1 gg of total RNA was reverse transcribed. The synthesis of the first strand cDNA was primed with random hexamers performed at 42°C for 1 h using 200 units M-MLV reverse transcriptase (Promega, Madison, WI, USA). After RNAase H treatment of the RNA/DNA hybrid, one half of the cDNA was used for PCR amplification in a 100-,tl reaction mix containing 50 pmol of each primer, 2. Owing to this exon connection strategy, DNAase I treatment of the initial template had no effect on the resulting PCR products. To confirm the integrity of the RNA used to generate the cDNAs and to check for equivalent efficiency of amplification all RT-PCR experiments were performed using sets of primers specific for the f-actin as well as the glucose 6-phosphate dehydrogenase (G6PD) housekeeping genes (Persico et al, 1981; Nakajima-lijima et al, 1985; Adams et al, 1992) , which are located on chromosomes X and 7 respectively. Both genes code for highly conserved proteins.
P-Actin is found in abundance in eukaryotic cells, whereas G6PD
is normally expressed at a very low level accounting for less than 0.1I% of total RNA. RT-PCR experiments were done as a biplex PCR, i.e. PCR reactions were run containing the DCC-specific primers combined with /B-actin or G6PD specific sets of primers.
To exclude an interference of target and control primers resulting in a reduced rate of amplification of either gene product the volume of the RT reaction was split and the cDNAs were amplified separately with the DCC and control primers respectively. PCR products were sampled during the exponential phase of amplification, as could be demonstrated for DCC-specific primers as well as controls (data not shown). The RT-PCR experiments were finally carried out twice as a biplex PCR for each sample to check for reproducible results. Concentrations of control primers were 25 pmol l-1 each; experiments were performed under the above-mentioned conditions. Primers used were 5'-TTCCGCCATGGTTTTTAAATCA-3' (DCC sense), 5'-AGCCTCATTTTCAGCCACACA-3' (DCC antisense) (Fearon et al, 1990 ), 5'-ATTCATCATCATGGGTGCATCG-3' (G6PD sense), 5'-TGTTTGCGGATGTCAGCCACTGT-3' (G6PD antisense), 5'-TGCTATCCAGGCTGTGCTAT-3' (actin sense), 5'-GATGGAGTTGAAGGTAGTTT-3' (actin antisense).
In order to examine the specificity and the relative amount of the generated PCR product one-fifth (20 ptl) of each PCR reaction was electrophoresed and blotted onto a nylon membrane by capillary salt transfer using a lOxSSC solution (lxSSC=0.15 M sodium chloride/0.015 sodium citrate). Blots were hybridized with Ix106 c.p.m. of the [32P]CTP-labelled 1.65 DCC cDNA probe per ml at 65°C for 16 h. After hybridization blots were washed twice with 0.1 xSSC/0. 1% sodium dodecyl sulphate (SDS) at 60°C for 30 min and autoradiographed at 4°C for 12 h. DCC RT-PCR products from normal bone tissue were included in each set of probes as a positive control. Furthermore, after stripping off the DCC cDNA probe the co-amplified f-actin-specific PCR products were hybridized with 0.5 x 106 c.p.m. per ml of a 31P-labelled actin probe.
An aliquot of tg of total RNA from each normal bone specimen was reverse transcribed and the prepared cDNAs were serially diluted from 1:1 to 1:1000, and subsequently amplified under conditions identical to those described above.
RT-PCR data analysis
The intensity of individual autoradiographic signals of blotted PCR products was measured by densitometry scanning using a Shimadzu densitometer. The area under the curve of absorption (AUC of A) was calculated with computer assistance. In order to estimate the relative abundance of DCC transcripts, values were compared with the mean AUCs resulting from the serially diluted cDNAs from normal bone specimens (Figure 1) . 
Immunoprecipitation and immunoblot analysis of DCC expression
Unprocessed cell line and tissue lysates were precleared by incubation with purified mouse immunoglobulin and protein G/Sepharose (Pharmacia, Germany). The supematant was incubated with protein G/Sepharose and DCC-specific monoclonal antibodies (15 gg ml', mouse, PharMingen, Hamburg) directed against extra-and intracytoplasmic domains (DCC antibodies and protein G/Sepharose were incubated for 4-6 h before). DCCspecific immunoprecipitates were recovered, washed, resuspended in Laemmli's sample buffer, and then subjected to SDS polyacrylamide gel electrophoresis (PAGE). The protein was transferred to a nitrocellulose membrane (Schleicher & Schuell, Dassel) by a semidry transblot system (Biometra, Gottingen). The DCC protein in the immunoprecipitates was detected by the ECL immunoblot assay (Amersham, Braunschweig) and subsequent exposure to Hyperfilm-JMax (Amersham).
Immunohistochemical analysis of DCC expression
For immunohistochemistry, paraffin-embedded specimens of osteosarcoma were available from 13 patients. Immunohistochemistry (IHC) was performed using the alkaline-antialkaline phosphatase (APAAP) system as described previously (Cordell et al, 1984) . Briefly, undecalcified 4-gm sections were dewaxed in xylene and rehydrated in descending concentrations of ethanol. For antigen retrieval of the DCC epitope, samples were boiled in a microwave oven (750 W) for 10 min in citrate buffer (0.1 M; pH 6.0). After extensive washing in Tris-buffered saline (145 mm sodium chloride, 20 mm Tris; pH 7.5) the sections were exposed to the primary antibody (mouse, monoclonal, 8 jig ml-', PharMingen, no. 15041 A). A secondary rabbit anti-mouse antibody (Dako, Hamburg) followed by the APAAP complex (Dako) was used for detection. Naphtol-AS-biphosphate (Sigma-Aldrich, Deisenhofen) and Neufuchsin (Merck, Darmstadt) were used for Table 2 The relative abundance of DCC-specific transcripts was determined by a semiquantitative RT-PCR-based assay. After Southern transfer, DCC PCR products were hybridized with a 32P-CTP-labelled DCC cDNA. The intensity of the autoradiographic signals, which reflect the relative amounts of DCC transcripts, was measured densitometrically as the area under the curve of absorption AUC (A). AUCs were compared with AUC (A) values based on DCC PCR data from serially diluted cDNAs of normal osseous tissue specimens (Figure 1) (Figure 1) .
The analysis of DCC specific RT-PCR products by gel electrophoresis is demonstrated in Figure 2A and B), which presents a selection of osteosarcomas and tumour cell lines. As expected, the British Journal of Cancer (1997) 75(9) Southern blot analyses of DCC PCR products ( Figure 2C ) that were used for semiquantitation proved more sensitive than the ingel measurement of PCR fragments ( Figure 2B ). Table 3 gives an overview of DCC RT-PCR data from normal osseous tissue, tumour specimens and cell lines. Eight out of 19 high-grade osteosarcomas (six primary tumours, two lung metastases; OS 12-19) had a nearly total extinction of DCC expression with a relative abundance of DCC transcripts of less than 1 % of normal osseous tissue cells as estimated from the cDNA dilution graph delineated in Figure 1 . In another six high-grade osteosarcomas (four primary tumours, one metastasis each in lung and spine; OS6-11) the DCC transcription was found to be reduced to less than 5% of normal. A normal or even increased DCC expression was found in the remaining five high-grade osteosarcomas comprising three primary tumours and two lung metastases (OS 1-5). Among the three periosteal intermediate-grade osteosarcomas, two tumours were found to have decreased or almost undetectable DCC expression (OS21, 22). Two out of three low-grade osteosarcoma specimens (OS24, 25) revealed reduced levels of DCC to varying degrees, whereas OS23 was found to express DCC transcripts within the range of normal bone tissue.
In three cases, two different tumour specimens from one patient each were analysed by RT-PCR. The lung metastases of patient no. 5 almost completely lost the DCC expression within 1 year of progressive disease (OS5, 19) . In patient no. 19 the primary intermediate-grade osteosarcoma initially exhibited a strong DCC expression, which was lost when the tumour recurred 4 months later (OS20, 21; Figure 2A) . The low-grade osteosarcoma OS24 represents a second local relapse with a rather low level of DCC expression which was found to be somewhat higher in its concomitant lung metastasis specimen (OS25).
Most of the cell lines investigated in this study demonstrated very low or even absent DCC expression, that is TE 85, Wo-OS, Saos-2, U2-OS, A-204, SW 403, SW 948, SW 11 16, HCT 116 and CCRF-CEM. The colon carcinoma cell lines SW 1463 and SW48, as well as the Ewing's sarcoma cell line RD-ES, showed easily detectable DCC transcripts but at a lower level than that found in normal osteoblasts.
DCC protein expression
The initial studies of endogenous DCC protein expression were performed on a variety of cell lines (TE 85, Saos-2, U2-OS, British Journal of Cancer (1997) 75(9) Figure 3A and B) . Using the combined immunoprecipitation and immunoblot assay, DCC protein expression was not detectable in a variety of normal osseous tissues or osteosarcomas revealing high levels of DCC transcription ( Figure 3A) . Immunohistochemical analysis, however, proved to be more sensitive than the immunoblot approach. The DCC protein could be clearly demonstrated in normal osteoblasts/osteocytes ( Figure  4A ). Moreover, in a subset of 14 available osteosarcomas (see Table 3 ) DCC protein expression correlated well with the level of DCC transcription based on an RT-PCR approach (Figure 4B-D) . In normal tissues, the most pronounced staining for DCC was found in mature osteocytes/osteoblasts. A less intensive DCC immunoreactivity was observed in immature mesenchymal cells presumably differentiating to osteoblastic cells ( Figure 4A ). Additionally, a faint to moderately intense staining was found in macrophages, fibroblasts and sometimes in endothelial cells as cellular components of granulation tissues (data not shown).
DCC rearrangement analysis
To determine whether the abnormalities of DCC expression could be related to any gross structural rearrangements we performed Southern blot analyses of EcoRI-restricted genomic DNA using the 1.65 DCC cDNA as described above. Originally, this probe was the longest clone that was isolated during the construction of a DCC cDNA library from RNA of a colon carcinoma cell line (Fearon et al, 1990) . Gross (Klingelhutz et al, 1994 ).
In colon carcinoma, a loss of DCC expression can be considered a late event in tumour progression (Kikuchi-Yanoshita et al, 1992) . Moreover, it has been suggested that DCC may act as a metastatic suppressor in colon carcinoma (Ookawa et al, 1993 Reale et al, 1994 (Fearon et al, 1990 ).
These differences may be attributable to an inconsistent mutational inactivation of the DCC gene or aberrant alternative DCC mRNA splicing processes, which were described previously (Reale et al, 1994 1.65-kb DCC cDNA probe we were not able to demonstrate any rearrangement or deletion in EcoRI-restricted genomic DNA from osteosarcoma. This probe, however, does not fully constitute the open reading frame of 4341 bp of the DCC gene, and thus neither rearrangements outside this region nor subtle alterations within would be detected. More comprehensive studies using a set of polymorphic 18q probes and mapping strategies in addition to an exhaustive mutational analysis of the 1.4 Mb DCC gene may be necessary to search for specific DNA alterations leading to a decreased DCC transcription in human osteosarcoma. In view of the enormous size of the DCC gene, mutational analysis is probably the most laborious way to look for alterations that may specifically inactivate DCC as a tumour-suppressor gene at DNA level.
The hitherto evaluated portions of the DCC sequence compose less than 1% of the gene E Fearon, 1996, personal communication) . Furthermore, studies on DCC RNA processing should complement our approach to the DCC gene in osteosarcoma, as aberrant alternative splicing of DCC mRNA appears to play a role in other malignancies (Reale et al, 1994; Ekstrand et al, 1995) . Finally, the functional restoration of the DCC gene in DCCdeficient osteosarcoma cells will be of great interest in order to provide further evidence that DCC serves as a tumour-suppressor gene in human osteosarcoma and that the loss or decrease of its expression is more than an epigenetic phenomenon.
